jolkinolide b profile

jolkinolide B: isolated from Euphorbia fischeriana [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Related Flora

Flora	Rank	Flora Definition	Family	Family Definition
Euphorbia	genus	A large plant genus of the family EUPHORBIACEAE, order Euphorbiales, subclass Rosidae. They have a milky sap and a female flower consisting of a single pistil surrounded by numerous male flowers of one stamen each. Euphorbia hirta is rarely called milkweed but that name is normally used for ASCLEPIAS.[MeSH]	Euphorbiaceae	The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH]
Euphorbia fischeriana	species	[no description available]	Euphorbiaceae	The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH]

ID Source	ID
PubMed CID	161954
CHEMBL ID	404387
CHEBI ID	69827
MeSH ID	M0161802

Synonym
jolkinolide b
bisoxireno[1,4]phenanthro[3,2-b]furan-9(7ah)-one, 1,2, 3,4,4a,5,6,11a,11b,11c-decahydro-4,4,8,11c-tetramethyl-, [4ar-(4a.alpha.,6as,7a.beta.,10ar,11a.beta.,11b.alpha.,11c.beta,)]-
NCI60_035896
nsc700087
nsc-700087
chebi:69827 ,
CHEMBL404387
37905-08-1
A7147
bisoxireno(1,10a:3,4)phenanthro(3,2-b)furan-9(7ah)-one, 1,2,3,4,4a,5,6,11a,11b,11c-decahydro-4,4,8,11c-tetramethyl-, (4ar-(4aalpha,6as,7abeta,10ar,11abeta,11balpha,11cbeta))-
4,4,8,11b-tetramethyl-2,3,4,4a,5,6,6a,7,10a,11,11a,11b-dodecahydro- 1h,9h-6a:7,10a:11-diepoxyphenanthro[3,2-b]furan-9-one
AKOS032946071
Q27138168
HY-N0732
(1s,3r,8r,10r,11r,12r,17r)-5,12,16,16-tetramethyl-2,7,9-trioxahexacyclo[9.8.0.01,3.04,8.08,10.012,17]nonadec-4-en-6-one
CS-0009745
MS-24967
DTXSID70958923
4,4,8,11c-tetramethyl-1,2,3,4,4a,5,6,11a,11b,11c-decahydrobisoxireno[3,4:1,10a]phenanthro[3,2-b]furan-9(7ah)-one
(4ar,6as,7ar,10ar,11ar,11br,11cr)-4,4,8,11c-tetramethyl-1,2,3,4,4a,5,6,11a,11b,11c-decahydrobis(oxireno)[2',3':1,10a;2'',3'':3,4]phenanthro[3,2-b]furan-9(7ah)-one
(1s,3r,8r,10r,11r,12r,17r)-5,12,16,16-tetramethyl-2,7,9-trioxahexacyclo[9.8.0.0,.0,.0,.0,nonadec-4-en-6-one

Role	Description
metabolite	Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
diterpene lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (21)

Assay ID	Title	Year	Journal	Article
AID1707203	Cytotoxicity against human HeLa cells	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1707208	Antitumor activity against mouse B16-F10 cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 20 mg/kg, IG administered for 7 days relative to control	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1490879	Antimycobacterial activity against Mycobacterium smegmatis after 24 hrs by microplate alamar blue assay	2017	Journal of natural products, 05-26, Volume: 80, Issue:5	ent-Abietane and Tigliane Diterpenoids from the Roots of Euphorbia fischeriana and Their Inhibitory Effects against Mycobacterium smegmatis.
AID1707188	Cytotoxicity against human MCF7 cells incubated for 48 hrs by sulforhodamine B staining based spectrophotometric assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1707189	Cytotoxicity against human UACC-62 cells incubated for 48 hrs by sulforhodamine B staining based spectrophotometric assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1707209	Antitumor activity against mouse B16-F10 cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 40 mg/kg, IG administered for 7 days relative to control	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1707202	Cytotoxicity against human HCT-15 cells incubated for 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1286240	Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at nitric oxide IC50 level by MTT assay	2016	Journal of natural products, Jan-22, Volume: 79, Issue:1	Diterpenoids from the Roots of Euphorbia fischeriana with Inhibitory Effects on Nitric Oxide Production.
AID1267732	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	ent-Abietane-type diterpenoids from the roots of Euphorbia ebracteolata with their inhibitory activities on LPS-induced NO production in RAW 264.7 macrophages.
AID1707187	Cytotoxicity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID328148	Cytotoxicity against human BGC 823 cells by MTT assay	2008	Journal of natural products, Feb, Volume: 71, Issue:2	Diterpenoids from the roots of Suregada glomerulata.
AID1286239	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells after 24 hrs by Griess assay	2016	Journal of natural products, Jan-22, Volume: 79, Issue:1	Diterpenoids from the Roots of Euphorbia fischeriana with Inhibitory Effects on Nitric Oxide Production.
AID1707201	Cytotoxicity against human LNCaP C4-2B cells incubated for 48 hrs by MTT assay	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID1267733	Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at IC50 by MTT assay	2016	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 26, Issue:1	ent-Abietane-type diterpenoids from the roots of Euphorbia ebracteolata with their inhibitory activities on LPS-induced NO production in RAW 264.7 macrophages.
AID1332165	Cytotoxicity against human Hep3B cells assessed as cell growth inhibition by MTT assay
AID328146	Cytotoxicity against human A549 cells by MTT assay	2008	Journal of natural products, Feb, Volume: 71, Issue:2	Diterpenoids from the roots of Suregada glomerulata.
AID328149	Cytotoxicity against human HCT8 cells by MTT assay	2008	Journal of natural products, Feb, Volume: 71, Issue:2	Diterpenoids from the roots of Suregada glomerulata.
AID1707207	Antitumor activity against mouse B16-F10 cells allografted in C57BL/6 mouse assessed as tumor growth inhibition at 10 mg/kg, IG administered for 7 days relative to control	2020	Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24	Development of Potential Antitumor Agents from the Scaffolds of Plant-Derived Terpenoid Lactones.
AID328150	Cytotoxicity against human A2780 cells by MTT assay	2008	Journal of natural products, Feb, Volume: 71, Issue:2	Diterpenoids from the roots of Suregada glomerulata.
AID1332166	Cytotoxicity against human A549 cells assessed as cell growth inhibition by MTT assay
AID328147	Cytotoxicity against human Bel 7402 cells by MTT assay	2008	Journal of natural products, Feb, Volume: 71, Issue:2	Diterpenoids from the roots of Suregada glomerulata.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (2.86)	18.7374
1990's	1 (2.86)	18.2507
2000's	5 (14.29)	29.6817
2010's	19 (54.29)	24.3611
2020's	9 (25.71)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	35 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pimagedine pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure. aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.	2.13	1	guanidines; one-carbon compound	EC 1.14.13.39 (nitric oxide synthase) inhibitor; EC 1.4.3.4 (monoamine oxidase) inhibitor
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	2.04	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.53	2	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.54	2	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	2.15	1	kanamycins	bacterial metabolite
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	2.03	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
thiazoles [no description available]	2.03	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	2.03	1	organic bromide salt	colorimetric reagent; dye
triptonide triptonide: extracted from Tripterygium wilfordii; structure given in first source. triptonide : A diterpene triepoxide that is triptobenzene K in which the acylhydroquinone moiety has undergone oxidation to the corresponding triepoxyketone derivative. It has been isolated from the roots of Tripterygium wilfordii.	2.25	1	butenolide; cyclic ketone; diterpene triepoxide; organic heteroheptacyclic compound	anti-inflammatory agent; antineoplastic agent; immunosuppressive agent
nagilactone c nagilactone C: norditerpene lactone isolated from leaves of Podocarpus; structure	2.25	1
brusatol brusatol: quassinoid from B. javanica; structure	2.25	1	triterpenoid
triptolide [no description available]	2.25	1	diterpenoid; epoxide; gamma-lactam; organic heteroheptacyclic compound	antispermatogenic agent; plant metabolite
parthenolide [no description available]	2.25	1	germacranolide
obacunone obacunone: from bark of Chinese plant Phellodendron amurense; shortens sleeping time induced in mice by alpha-chloralose-urethane	2.25	1	limonoid
chlorolissoclimide chlorolissoclimide: structure given in first source; a labdane cytotoxin isolated from Lissoclinum voeltzkowi Michaelson	2.25	1
bruceine a bruceine A: quassinoid which inhibits protein synthesis & DNA synthesis in cells; RN given refers to (11 beta,12 alpha,15 beta)-isomer; structure given in first source	2.25	1	quassinoid
bruceine b bruceine B: quassinoid which inhibits protein synthesis & DNA synthesis in cells; structure in first source	2.25	1	triterpenoid
jolkinolide a jolkinolide A: isolated from Euphorbia fischeriana	3.33	6	diterpene lactone	metabolite
limonin [no description available]	2.25	1	epoxide; furans; hexacyclic triterpenoid; lactone; limonoid; organic heterohexacyclic compound	inhibitor; metabolite; volatile oil component
tripdiolide tripdiolide: structure	2.25	1	oxacycle
ingenol [no description available]	2.13	1	cyclic terpene ketone; tetracyclic diterpenoid
thapsigargin Thapsigargin: A sesquiterpene lactone found in roots of THAPSIA. It inhibits SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES.. thapsigargin : An organic heterotricyclic compound that is a hexa-oxygenated 6,7-guaianolide isolated fron the roots of Thapsia garganica L., Apiaceae. A potent skin irritant, it is used in traditional medicine as a counter-irritant. Thapsigargin inhibits Ca(2+)-transporting ATPase mediated uptake of calcium ions into sarcoplasmic reticulum and is used in experimentation examining the impacts of increasing cytosolic calcium concentrations.	2.25	1	butyrate ester; organic heterotricyclic compound; sesquiterpene lactone	calcium channel blocker; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor
12-deoxyphorbol 13-acetate [no description available]	2.15	1	phorbol ester	metabolite
phorbol 13-monoacetate phorbol 13-monoacetate: RN given refers to (1aR-(1aalpha,1bbeta,4abeta,7aalpha,7balpha,8alpha,9beta,9aalpha)-isomer); RN for cpd without isomeric designation not in Chemlne 11/86	2.15	1	phorbol ester
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	2.07	1	prostaglandins E	human metabolite; mouse metabolite; oxytocic
bruceantin [no description available]	2.25	1	triterpenoid
andrographolide [no description available]	2.25	1	carbobicyclic compound; gamma-lactone; labdane diterpenoid; primary alcohol; secondary alcohol	anti-HIV agent; anti-inflammatory drug; antineoplastic agent; metabolite
shihulimonin a shihulimonin A: isolated from Evodia rutaecarpa; structure in first source	2.25	1	limonoid
dichapetalin a dichapetalin A: isolated from Dichapetalum; structure in first source	2.25	1
ginkgolide b [no description available]	2.25	1
17-hydroxyjolkinolide b 17-hydroxyjolkinolide B: isolated from Euphorbia fischeriana	2.98	4	diterpene lactone	metabolite
bn 52020 [no description available]	2.25	1
dichlorolissoclimide dichlorolissoclimide: structure given in first source; a labdane cytotoxin isolated from Lissoclinum voeltzkowi Michaelson	2.25	1
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.07	1
14-o-phosphonooxymethyltriptolide 14-O-phosphonooxymethyltriptolide disodium salt: pro-drug of triptolide; has antineoplastic activity	2.25	1

Condition	Relationship Strength	Studies
Benign Neoplasms [description not available]	2.5	2
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.5	2
Breast Cancer [description not available]	7.81	3
Breast Neoplasms Tumors or cancer of the human BREAST.	2.81	3
Cancer of Larynx [description not available]	2.31	1
Laryngeal Neoplasms Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.	2.31	1
Bladder Cancer [description not available]	2.76	2
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.76	2
Cirrhosis [description not available]	2.41	1
Ureteral Obstruction Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.	7.41	1
Fibrosis Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.	7.41	1
Cancer of Lung [description not available]	2.89	3
Lung Neoplasms Tumors or cancer of the LUNG.	2.89	3
Cancer of Stomach [description not available]	2.41	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.41	1
Carcinoma, Non-Small Cell Lung [description not available]	2.17	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.17	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.1	1
Bone Loss, Osteoclastic [description not available]	2.1	1
Innate Inflammatory Response [description not available]	2.1	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.1	1
Lung Injury, Acute [description not available]	2.11	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.11	1
Acute Lung Injury A condition of lung damage that is characterized by bilateral pulmonary infiltrates (PULMONARY EDEMA) rich in NEUTROPHILS, and in the absence of clinical HEART FAILURE. This can represent a spectrum of pulmonary lesions, endothelial and epithelial, due to numerous factors (physical, chemical, or biological).	7.11	1
B16 Melanoma [description not available]	2.13	1
Adenocarcinoma, Alveolar [description not available]	2.15	1
Adenocarcinoma, Bronchiolo-Alveolar A carcinoma derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)	2.15	1
Leucocythaemia [description not available]	2.06	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.06	1
Cancer of Nasopharynx [description not available]	2	1
Nasopharyngeal Neoplasms Tumors or cancer of the NASOPHARYNX.	2	1
Cancer of Prostate [description not available]	2.01	1
Prostatic Neoplasms Tumors or cancer of the PROSTATE.	2.01	1

jolkinolide b

Description

Cross-References

Synonyms (21)

Roles (1)

Drug Classes (1)

Bioassays (21)

Research

Studies (35)

Study Types

jolkinolide b

Description

Related Flora

Cross-References

Synonyms (21)

Roles (1)

Drug Classes (1)

Bioassays (21)

Research

Studies (35)

Study Types

Related Drugs (35)

Related Conditions (33)